Sugi Predict

Sugi Predict / Targets / SLC1A5

SLC1A5

Neutral amino acid transporter B(0) · Q15758 · SLC1A5 on Sugi Atlas →

5,410 patent compounds predicted against SLC1A5, 3,159 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2238701 SCHEMBL2238701 0.56 20/20
SCHEMBL1769644 SCHEMBL1769644 0.53 15/20
SCHEMBL1769648 SCHEMBL1769648 0.53 15/20
SCHEMBL2838808 SCHEMBL2838808 0.36 9/20
SCHEMBL996075 SCHEMBL996075 0.60 8/20
SCHEMBL2279909 SCHEMBL2279909 0.48 8/20
SCHEMBL5157377 SCHEMBL5157377 0.46 8/20
SCHEMBL5157382 SCHEMBL5157382 0.46 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1023741) 0.45 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4847778) 0.45 8/20
SCHEMBL1666512 SCHEMBL1666512 0.57 7/20
SCHEMBL209885 SCHEMBL209885 0.46 7/20
SCHEMBL3855400 SCHEMBL3855400 0.41 7/20
SCHEMBL3855403 SCHEMBL3855403 0.41 7/20
SCHEMBL1666509 SCHEMBL1666509 0.51 6/20
SCHEMBL1666514 SCHEMBL1666514 0.45 6/20
SCHEMBL5248460 SCHEMBL5248460 0.40 6/20
SCHEMBL3621544 SCHEMBL3621544 0.54 5/20
SCHEMBL837541 SCHEMBL837541 0.43 5/20
SCHEMBL837542 SCHEMBL837542 0.43 5/20

Clinical trials — most relevant to SLC1A5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Kuvan on Melatonin Secretion PHASE4COMPLETED
Effect of Age on the Renal Clearance of Adefovir PHASE4WITHDRAWN
L-arginine Treatment in Mild Hypertension PHASE4UNKNOWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases PHASE2/PHASE3WITHDRAWN
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
FET-PET for Evaluation of Response of Recurrent GBM to Avastin PHASE2COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure PHASE2UNKNOWN
Study on Amino Acid Uptake in Brain Tumors PHASE2UNKNOWN
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® PHASE1/PHASE2COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy nanUNKNOWN
Nutrient Sensing & Signaling in Aging Muscle nanCOMPLETED
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital nanNOT_YET_RECRUITING
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU) nanUNKNOWN
FBY PET/CT in Patients With Brain Tumors nanUNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract nanCOMPLETED
PET-Guided Resection in High-Grade Gliomas nanRECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Brain P-gp and Inflammation in People With Epilepsy nanCOMPLETED
Characterization of Breg Cells nanCOMPLETED
Fluorescence and Glioma Heterogeneity nanCOMPLETED
Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease nanCOMPLETED
Neuroinflammation in COVID-19 and Depression nanCOMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC1A5 binder may also engage these)

ProteinNameSimilarity
Q4R8W8 — 1.000 Q4R8W8 →
Q95JC7 — 1.000 Q95JC7 →
P51912 — 0.997 P51912 →
O19105 — 0.993 O19105 →
A2VDL4 — 0.987 A2VDL4 →
O35874 — 0.985 O35874 →
P43007 — 0.985 P43007 →
D3ZJ25 — 0.980 D3ZJ25 →
Q9N1R2 — 0.980 Q9N1R2 →
P48664 — 0.977 P48664 →
O35921 — 0.976 O35921 →
O35544 — 0.974 O35544 →
O00341 — 0.971 O00341 →
Q8JZR4 — 0.970 Q8JZR4 →
O57321 — 0.967 O57321 →
P31596 — 0.964 P31596 →
P56564 — 0.963 P56564 →
P24942 — 0.961 P24942 →
SLC1A1 Excitatory amino acid transporter 3 0.961 landscape →
P49280 — 0.960 P49280 →
P46411 — 0.959 P46411 →
SLC1A3 Excitatory amino acid transporter 1 0.959 landscape →
SLC1A2 Excitatory amino acid transporter 2 0.959 landscape →
P31597 — 0.957 P31597 →
P56436 — 0.956 P56436 →
P51907 — 0.956 P51907 →
A1L3P4 — 0.954 A1L3P4 →
Q10901 — 0.954 Q10901 →
P51906 — 0.953 P51906 →
P43006 — 0.953 P43006 →